This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. IKT, PLX, IZTC, ACHL, ZIVO, BLUE, CRTX, CYTH, FNCH, and JATTShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Achilles Therapeutics (ACHL), ZIVO Bioscience (ZIVO), bluebird bio (BLUE), Cortexyme (CRTX), Cyclo Therapeutics (CYTH), Finch Therapeutics Group (FNCH), and JATT Acquisition (JATT). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Achilles Therapeutics ZIVO Bioscience bluebird bio Cortexyme Cyclo Therapeutics Finch Therapeutics Group JATT Acquisition Inhibikase Therapeutics (NYSE:IKT) and Proteon Therapeutics (NASDAQ:PRTO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Does the media prefer IKT or PRTO? In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Proteon Therapeutics. MarketBeat recorded 1 mentions for Inhibikase Therapeutics and 0 mentions for Proteon Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.45 beat Proteon Therapeutics' score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Inhibikase Therapeutics Neutral Proteon Therapeutics Neutral Is IKT or PRTO more profitable? Proteon Therapeutics' return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -350.63% -201.82% Proteon Therapeutics N/A N/A -118.68% Do analysts recommend IKT or PRTO? Inhibikase Therapeutics presently has a consensus target price of $6.50, suggesting a potential upside of 233.33%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, IKT or PRTO? Inhibikase Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Proteon Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Do insiders and institutionals hold more shares of IKT or PRTO? 3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 23.0% of Proteon Therapeutics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 45.7% of Proteon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, IKT or PRTO? Inhibikase Therapeutics has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K557.57-$19.03M-$2.67-0.73Proteon TherapeuticsN/AN/A-$20.73M-$1.15-2.63 SummaryInhibikase Therapeutics beats Proteon Therapeutics on 9 of the 14 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.20M$200.83M$5.52B$8.86BDividend YieldN/AN/A5.36%4.13%P/E Ratio-2.63N/A26.3919.77Price / SalesN/A236.07408.83110.45Price / CashN/A22.4425.8827.49Price / Book-50.505.567.915.36Net Income-$20.73M-$96.61M$3.15B$248.34M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.03+5.2%N/A+38.5%$67.20MN/A-2.6317IKTInhibikase Therapeutics1.2533 of 5 stars$1.66flat$6.50+291.6%+61.2%$123.41M$260K-0.626News CoveragePLXProtalix BioTherapeutics3.0134 of 5 stars$1.53+13.3%$15.00+880.4%+26.5%$121.80M$59.76M-11.77200News CoverageIZTCInvizyne TechnologiesN/A$10.50+14.8%N/AN/A$65.65MN/A0.0029ACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ZIVOZIVO Bioscience0.3517 of 5 stars$14.91+4.9%N/AN/A$56.85M$15.85K-3.0610Gap DownBLUEbluebird bio2.1543 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoverageCRTXCortexymeN/A$1.32+1.5%N/A+106.7%$39.80MN/A-0.4455CYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FNCHFinch Therapeutics Group0.3727 of 5 stars$13.00-0.1%N/A+863.5%$20.89M$110K-1.47190JATTJATT AcquisitionN/A$1.12-0.9%N/A-70.0%$19.32MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Inhibikase Therapeutics Alternatives Protalix BioTherapeutics Alternatives Invizyne Technologies Alternatives Achilles Therapeutics Alternatives ZIVO Bioscience Alternatives bluebird bio Alternatives Cortexyme Alternatives Cyclo Therapeutics Alternatives Finch Therapeutics Group Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
